SGLT-话题@MedSci

#SGLT#

125篇内容 | 2804人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格, objectType=article, longId=174322, objectId=0d4b1e4322ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d4b1e4322ee, replyNumber=0, likeNumber=62, createdTime=2020-03-22, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d4b1e4322ee, moduleTitle=慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d4b1e4322ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793830, encodeId=a3671e93830c5, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Lancet Diabetes Endo：SGLT2抑制剂的肾脏保护作用, objectType=article, longId=179046, objectId=34e61e9046bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34e61e9046bc, replyNumber=0, likeNumber=75, createdTime=2020-04-10, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34e61e9046bc, moduleTitle=Lancet Diabetes Endo：SGLT2抑制剂的肾脏保护作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34e61e9046bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793831, encodeId=84d71e938310e, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证, objectType=article, longId=179624, objectId=489d1e96248e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=489d1e96248e, replyNumber=0, likeNumber=69, createdTime=2019-09-22, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=489d1e96248e, moduleTitle=阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=489d1e96248e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793826, encodeId=8c0e1e9382670, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与生殖器真菌感染和尿路感染的风险, objectType=article, longId=174707, objectId=386c1e470775, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=386c1e470775, replyNumber=0, likeNumber=68, createdTime=2019-07-11, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=386c1e470775, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与生殖器真菌感染和尿路感染的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=386c1e470775)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793823, encodeId=78ad1e9382351, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=SGLT2降糖药致生殖器感染"发酵" 已上市药物几乎都中枪, objectType=article, longId=165872, objectId=18411658e2e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18411658e2e0, replyNumber=0, likeNumber=77, createdTime=2019-12-21, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18411658e2e0, moduleTitle=SGLT2降糖药致生殖器感染"发酵" 已上市药物几乎都中枪, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18411658e2e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793820, encodeId=b7a81e93820e7, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=JCEM：SGLT2抑制剂增加了糖尿病酮症酸中毒的风险, objectType=article, longId=161782, objectId=aad0161e82c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aad0161e82c0, replyNumber=0, likeNumber=99, createdTime=2019-03-08, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aad0161e82c0, moduleTitle=JCEM：SGLT2抑制剂增加了糖尿病酮症酸中毒的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aad0161e82c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793821, encodeId=ebe61e9382147, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请, objectType=article, longId=162858, objectId=f5fa1628585f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5fa1628585f, replyNumber=0, likeNumber=87, createdTime=2019-03-30, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5fa1628585f, moduleTitle=美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5fa1628585f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793818, encodeId=a90c1e9381810, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂对2型糖尿病和慢性肾病患者的心血管、肾脏和安全性结局的影响, objectType=article, longId=159506, objectId=5b8515950618, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b8515950618, replyNumber=0, likeNumber=98, createdTime=2019-07-29, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b8515950618, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂对2型糖尿病和慢性肾病患者的心血管、肾脏和安全性结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b8515950618)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793829, encodeId=16561e9382947, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=BMJ：SGLT2抑制剂可降低糖尿病患者心力衰竭风险, objectType=article, longId=178463, objectId=a7aa1e846397, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7aa1e846397, replyNumber=0, likeNumber=75, createdTime=2019-09-28, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7aa1e846397, moduleTitle=BMJ：SGLT2抑制剂可降低糖尿病患者心力衰竭风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7aa1e846397)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793822, encodeId=43d11e93822f9, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=70, createdTime=2019-07-31, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793827, encodeId=253a1e9382764, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病, objectType=article, longId=177009, objectId=bd4e1e700904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd4e1e700904, replyNumber=0, likeNumber=123, createdTime=2020-02-12, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd4e1e700904, moduleTitle=AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd4e1e700904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793828, encodeId=8c611e93828d8, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=SGLT2抑制剂达格列净在心衰研究中显示出益处, objectType=article, longId=178048, objectId=18661e804804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18661e804804, replyNumber=0, likeNumber=85, createdTime=2019-09-26, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18661e804804, moduleTitle=SGLT2抑制剂达格列净在心衰研究中显示出益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18661e804804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793815, encodeId=5f061e93815d3, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Lancet：SGLT2抑制剂对II型糖尿病患者心血管及肾功能的影响研究, objectType=article, longId=153311, objectId=986d15331165, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=986d15331165, replyNumber=0, likeNumber=52, createdTime=2019-06-20, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=986d15331165, moduleTitle=Lancet：SGLT2抑制剂对II型糖尿病患者心血管及肾功能的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=986d15331165)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793812, encodeId=17921e9381210, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：与SGLT2抑制剂相关的生殖器感染风险分析, objectType=article, longId=148897, objectId=5a5a14889e0f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a5a14889e0f, replyNumber=0, likeNumber=114, createdTime=2019-02-13, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a5a14889e0f, moduleTitle=Diabetes Obes Metab：与SGLT2抑制剂相关的生殖器感染风险分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a5a14889e0f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793819, encodeId=53231e93819d4, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=2019 国际共识：接受SGLT抑制剂治疗的1型糖尿病患者糖尿病酸中毒风险管理, objectType=article, longId=160685, objectId=e214160685ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e214160685ac, replyNumber=0, likeNumber=33, createdTime=2019-06-20, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e214160685ac, moduleTitle=2019 国际共识：接受SGLT抑制剂治疗的1型糖尿病患者糖尿病酸中毒风险管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e214160685ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793814, encodeId=db811e9381412, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=JACC：SGLT1基因突变引起的葡萄糖吸收减少可降低心血管代谢风险, objectType=article, longId=150389, objectId=170715038983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=170715038983, replyNumber=0, likeNumber=73, createdTime=2018-11-11, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=170715038983, moduleTitle=JACC：SGLT1基因突变引起的葡萄糖吸收减少可降低心血管代谢风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=170715038983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793807, encodeId=c7b01e9380700, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Cardiovasc Diabetol：SGLT2抑制剂可否降低2型糖尿病患者的心衰风险？, objectType=article, longId=145809, objectId=5cde145809a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cde145809a9, replyNumber=0, likeNumber=70, createdTime=2018-12-28, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cde145809a9, moduleTitle=Cardiovasc Diabetol：SGLT2抑制剂可否降低2型糖尿病患者的心衰风险？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cde145809a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793816, encodeId=a92d1e938162d, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Sci Transl Me：穿越！降糖靶点SGLT2竟然可以辅助肺腺癌早检，获批降糖药有望用于治疗, objectType=article, longId=153661, objectId=4d1e15366120, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d1e15366120, replyNumber=0, likeNumber=79, createdTime=2019-10-30, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d1e15366120, moduleTitle=Sci Transl Me：穿越！降糖靶点SGLT2竟然可以辅助肺腺癌早检，获批降糖药有望用于治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d1e15366120)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793809, encodeId=d72c1e9380936, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Lancet Gastroen Hepatol：SGLT1抑制剂mizagliflozin用于改善功能性便秘, objectType=article, longId=147525, objectId=198b14e52564, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=198b14e52564, replyNumber=0, likeNumber=61, createdTime=2019-05-23, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=198b14e52564, moduleTitle=Lancet Gastroen Hepatol：SGLT1抑制剂mizagliflozin用于改善功能性便秘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=198b14e52564)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793817, encodeId=76381e938176b, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=观察性研究中使用SGLT2抑制剂死亡风险较低：真实还是偏倚？, objectType=article, longId=159182, objectId=207b1591827c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=207b1591827c, replyNumber=0, likeNumber=65, createdTime=2019-04-21, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=207b1591827c, moduleTitle=观察性研究中使用SGLT2抑制剂死亡风险较低：真实还是偏倚？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=207b1591827c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT

2020-05-29

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格

2020-03-22

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Lancet Diabetes Endo：SGLT2抑制剂的肾脏保护作用

2020-04-10

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证

2019-09-22

一叶知秋 (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：SGLT2抑制剂与生殖器真菌感染和尿路感染的风险

2019-07-11

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

SGLT2降糖药致生殖器感染"发酵" 已上市药物几乎都中枪

2019-12-21

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

JCEM：SGLT2抑制剂增加了糖尿病酮症酸中毒的风险

2019-03-08

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请

2019-03-30

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：SGLT2抑制剂对2型糖尿病和慢性肾病患者的心血管、肾脏和安全性结局的影响

2019-07-29

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

BMJ：SGLT2抑制剂可降低糖尿病患者心力衰竭风险

2019-09-28

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2019-07-31

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病

2020-02-12

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

SGLT2抑制剂达格列净在心衰研究中显示出益处

2019-09-26

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Lancet：SGLT2抑制剂对II型糖尿病患者心血管及肾功能的影响研究

2019-06-20

仁心济世 (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：与SGLT2抑制剂相关的生殖器感染风险分析

2019-02-13

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

2019 国际共识：接受SGLT抑制剂治疗的1型糖尿病患者糖尿病酸中毒风险管理

2019-06-20

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

JACC：SGLT1基因突变引起的葡萄糖吸收减少可降低心血管代谢风险

2018-11-11

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Cardiovasc Diabetol：SGLT2抑制剂可否降低2型糖尿病患者的心衰风险？

2018-12-28

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Sci Transl Me：穿越！降糖靶点SGLT2竟然可以辅助肺腺癌早检，获批降糖药有望用于治疗

2019-10-30

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Lancet Gastroen Hepatol：SGLT1抑制剂mizagliflozin用于改善功能性便秘

2019-05-23

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

观察性研究中使用SGLT2抑制剂死亡风险较低：真实还是偏倚？

2019-04-21

科室
- - 订阅+
  - 更多科室
工具
服务